AKT1 and mycosis fungoides: In conclusion, GZ17-6.02 inhibits the growth of MF by modulating key drivers of multiple pathways such as MAPK, Pi3K/Akt/mTOR, and NF-κB signaling and represents a promising therapeutic option for the treatment of this disease.